期刊文献+

罗格列酮对2型糖尿病患者下肢动脉粥样硬化的影响

下载PDF
导出
摘要 目的观察罗格列酮对2型糖尿病(T2DM)患者下肢动脉粥样硬化的影响。方法135例T2DM患者随机分成两组,治疗组在原治疗基础上给予罗格列酮4 mg.d-1。治疗前及疗程(6个月)结束时检测空腹血糖(FBG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1C)和血脂水平,计算胰岛素抵抗指数(IRI)和胰岛素敏感指数(ISI),用彩色多普勒超声检查下肢动脉内中膜厚度(IMT)、管腔内径、斑块的数量和类型。结果治疗组FBG、FINS、甘油三酯、HbA1C均比治疗前明显降低(P<0.05),ISI显著上升(P<0.01),IRI显著下降(P<0.01)。治疗组双下肢动脉IMT降低,斑块数量和类型与治疗前及对照组比较均有统计学意义(均P<0.05)。结论罗格列酮治疗T2DM在降低血糖、改善IRI、提高ISI的同时,并在一定程度上延缓其下肢动脉粥样硬化斑块的发生和发展。
出处 《现代医学》 2009年第4期306-308,共3页 Modern Medical Journal
  • 相关文献

参考文献3

二级参考文献19

  • 1Whiteomb RW, Saltiel AR. Thiazolidinediones. Exp Opin Invest Drugs, 1995,4 : 1299-1309.
  • 2lmura H. A novel antidiabetic drug, troglitazone-reason for hope and concern. New Engl J Med, 1998,338:908-909.
  • 3Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2.diabetic patients. Diabetic Med, 2000,17:40-47.
  • 4Narayan KMV, Gregg EW, Fagot-Campagna A, et al. Diabetes-a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract, 2000,50 ( Suppl 2 ) : S77-S84.
  • 5Turner RC, Cull CA, Frighi V, Glycemic control with diet, sulfonylurea, mefformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies ( UKPDS 49), JAMA1999,281:2005-2012.
  • 6Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulphonylureas. Diabetes, 2001,50 : A542.
  • 7Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Met Res Rev, 2002,18 : 127-134.
  • 8Barnett A. Rosiglitazone in type 2 diabetes: an evaluation in British lndo-Asian patients. Diabetic Med, 2001,18 :A40.
  • 9Dogterum P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythrupoiesis or premature red cell destruction. Diabetes, 1999,48 :A98.
  • 10Samraj GP, Kuritzky L, Quillen DM. Improving management of type 2 diabetes mellitus : 5. Thiazolidinediones. Hosp Pract, 2000,35 : 123-124.

共引文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部